Publications

363 publications

Enter search criteria

Fill in keyword(s) to narrow your search.

Period
Period

You can select a specific type of a publication you are looking for, such as press releases or speeches

Sort by:
  1. Package advice cemiplimab (Libtayo®) for the treatment of non-small cell lung carcinoma (NSCLC)

    Zorginstituut Nederland has completed its assessment whether cemiplimab (Libtayo®) as primary care treatment for stage IIIBC-IV ...

    Report | 26-10-2021

  2. GVS assessment empagliflozin (Jardiance®) for the treatment of adults with chronic heart failure

    The National Health Care Institute recommends the Minister for Medical Care to extend the reimbursement condition of ...

    Report | 21-10-2021

  3. GVS review levomepromazine (Nozinan®) for palliative sedation in a home situation

    Zorginstituut Nederland has completed its assessment whether the substance levomepromazine (Nozinan®) can be included in the ...

    Report | 29-09-2021

  4. Extension of further conditions for SGLT2 inhibitors following recent GVS advice (22 June 2021)

    Zorginstituut Nederland has completed its assessment whether the further conditions of SGLT-2 inhibitors canagliflozin ...

    Report | 20-09-2021

  5. GVS advice CGRP inhibitors erenumab, fremanezumab, galcanezumab (Aimovig®, AJOVY®, Emgality®) for the treatment of patients with episodic and chronic migraine

    The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

    Report | 17-09-2021

  6. GVS advice roxadustat (Evrenzo®) for the treatment of symptomatic anaemia in chronic kidney damage

    The National Health Care Institute has completed its assessment (using the CBG-ZIN parallel procedure) whether roxadustat ...

    Report | 03-09-2021

  7. GVS advice drospirenon-estetrol (Drovelis®)

    The National Health Care Institute has completed its assessment whether drospirenon/estetrol (Drovelis®) is interchangeable with ...

    Report | 31-08-2021

  8. Follow-up advice on conditional inclusion of larotrectinib (Vitrakvi®)

    Zorginstituut Nederland recommends that larotrectinib (Vitrakvi®) should be conditionally included in the basic health care ...

    Report | 16-08-2021

  9. Follow-up advice on conditional inclusion of entrectinib (Rozlytrek®)

    Zorginstituut Nederland recommends that entrectinib (Rozlytrek®) should be conditionally included in the basic health care ...

    Report | 16-08-2021

  10. Package advice ipilimumab (Yervoy®) in combination with nivolumab (Opdivo®)

    The National Health Care Institute has completed its assessment whether ipilimumab (Yervoy®) in combination with nivolumab ...

    Report | 11-08-2021